Results 121 to 130 of about 33,145 (233)

Gamma‐irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy

Immunology &Cell Biology, EarlyView.
To overcome biological risks associated with using live NDV as an oncolytic therapy, we developed gamma‐NDV as a safer alternative. Using a murine model for skin cancer, we show that intratumor administration of gamma‐NDV outperformed live‐NDV in terms of reducing tumor growth and improving overall animal survival. Abstract Newcastle disease virus (NDV)
Eve V Kennedy, Yimin Chuah, Amal H Mostafa, Chloe J Gates, Jade Foeng, Todd S Norton, Shaun R McColl, Iain Comerford, Justin B Davies, Farhid Hemmatzadeh, Mohammed Alsharifi   +10 more
wiley   +1 more source

Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus

Bladder Cancer, 2015
Purpose: Despite recent improvements, resistance to traditional immunotherapy or chemotherapy is still common in patients with bladder cancer. We constructed an oncolytic virus from herpes simplex virus type II (HSV-2), which selectively targets tumor ...
Kwan Joong Joo, Hongtao Li, Xiaoliu Zhang, Seth P. Lerner   +3 more
doaj   +1 more source

Viral hijacking of cellular metabolism. [PDF]

, 2019
This review discusses the current state of the viral metabolism field and gaps in knowledge that will be important for future studies to investigate.
Ch'ng, James, Christofk, Heather R, Thaker, Shivani K   +2 more
core  

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

Oncolytic vaccinia virus and cancer immunotherapy

Frontiers in Immunology
Oncolytic virotherapy (OVT) is a promising form of cancer treatment that uses genetically engineered viruses to replicate within cancer cells and trigger anti-tumor immune response. In addition to killing cancer cells, oncolytic viruses can also remodel the tumor microenvironment and stimulate a long-term anti-tumor immune response.
Lihua Xu, Huihui Sun, Nicholas R. Lemoine, Nicholas R. Lemoine, Yujing Xuan, Pengju Wang   +5 more
openaire   +3 more sources

Multiple Myeloma : an update on disease biology and therapy [PDF]

, 2004
Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Cook, Rachel J., Dingli, David
core  

Artificially cloaked viral nanovaccine for cancer immunotherapy

Nature Communications, 2019
Cancer therapy using oncolytic virus has shown pre-clinical and clinical efficacy. Here, the authors report ExtraCRAd, an oncolytic virus cloaked with tumour cell membrane and report its therapeutic effects in vitro and in vivo in multiple mouse tumour ...
Manlio Fusciello, Flavia Fontana, Siri Tähtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylösmäki, Erkko Ylösmäki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Hélder A. Santos, Vincenzo Cerullo   +17 more
doaj   +1 more source

‘BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026

BJU International, EarlyView.
Vignesh T. Packiam, Peter C. Black, James W. F. Catto, Saum Ghodoussipour, Max Kates, Ashish M. Kamat, Yair Lotan, Michael A. O’Donnell, Jeremy Y. C. Teoh, George N. Thalmann, Stephen B. Williams   +10 more
wiley   +1 more source

Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review

Vaccines
Checkpoint inhibitor therapy revolutionized the treatment of patients with melanoma. However, in patients where melanoma exhibits resistance to checkpoint inhibitor therapy, the treatment options are limited.
Ayushi Garg, Rohit Rao, Felicia Tejawinata, Gazi Amena Noor Shamita, McKay S. Herpel, Akihiro Yoshida, Gordon Goolamier, Jessica Sidiropoulos, Iris Y. Sheng, Salim-Tamuz Abboud, Luke D. Rothermel, Nami Azar, Ankit Mangla   +12 more
doaj   +1 more source

Improving oncolytic adenoviral therapies for gastrointestinal cancers and tumor initiating cells [PDF]

, 2010
Although the treatment of most cancers has improved steadily, only few metastatic solid tumors can be cured. Despite responses, refractory clones often emerge and the disease becomes refractory to available treatment modalities.
Kangasniemi, Lotta
core